Differential effects of current specific treatments on behavioral and psychological symptoms in patients with alzheimer's disease: A 12-month, randomized, open-label trial

Journal of Alzheimer's Disease

Volumn 39, Issue 3, 2014, Pages 477-485

  Cumbo, Eduardo ^a   Ligori, Leonarda Domenica ^a  

^a ASP Caltanissetta   (Italy)

Author keywords

Alzheimer's disease; behavioral and psychological symptoms; donepezil; galantamine; memantine; rivastigmine

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; ARTICLE; BEHAVIOR DISORDER; BEHAVIORAL PATHOLOGY IN ALZHEIMER DISEASE SCALE; CONFUSION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; INSOMNIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; NAUSEA; NEUROPSYCHIATRIC INVENTORY; OPEN STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHOBIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SEDATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERY ELDERLY; VOMITING;

ALZHEIMER'S DISEASE; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; CHOLINESTERASE INHIBITORS; DEMENTIA; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; GALANTAMINE; HUMANS; INDANS; LONGITUDINAL STUDIES; MALE; MEMANTINE; MENTAL DISORDERS; PHENYLCARBAMATES; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 84894154111     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131190     Document Type: Article

References (24)

1. Lyketsos CG, Lopez O, Jones B, Fitzpatrick A, Breitner J, Dekosky S (2002) Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA 288, 1475-1483.
2. Lanari A, Amenta F, Silvestrelli G, Tomassoni D, Parnetti L (2006) Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech Ageing Dev 127, 158-165.
3. Kozman M, Wattis J, Curran S (2006) Pharmacological management of behavioral and psychological disturbance in dementia. Hum Psychopharmacol Clin Exp 21, 1-12.
4. Hemels ME, Lanctot KL, Iskedjian M, Einarson TR (2001) Clinical and economic factors in the treatment of behavioral and psychological symptoms of dementia. Drugs Aging 18, 527-550.
5. Ballard C, Waite J (2006) The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev, CD003476.
6. Gauthier S, Loft H, Cummings J (2008) Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: A pooled data analysis. Int J Geriatr Psychiatry 23, 537-545.
7. Aupperle P, Koumaras B, Chen M, Rabinowicz A, Mirski D (2004) Long term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: Results of a 52-week open-label study. Curr Med Res Opin 20, 1605-1612.
8. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp M, Lindesay J, O'Brien JT, Wilcock G, Katona C, Jones RW, DeCesare J, Rodger M (2007) Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 357, 1382-1392
9. Brodaty H, Corey-Bloom J, Potocnik FC, Truyen L, Gold M, Damaraju CR (2005) Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 20, 120-132.
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosisof Alzheimer's disease: Report of the NINCDS-ARDRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34, 939-944.
11. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine inmoderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341.
12. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W (2004) Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 161, 532-538.
13. McKeith I, Del Ser T, Spano PF, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000) Efficacy of rivastigmine in dementia with Lewy bodies: A randomized, double-blind, placebo-controlled, international study. Lancet 356, 2031-2036.
14. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Oliv-eri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J (2004) The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer's disease. Neurology 63, 214-219.
15. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld FCP, Ding C, The Galantamine USA-10 Study Group (2000) A 5-month, randomized, placebo-controlled trial of galan-tamine in Alzheimer's disease. Neurology 54, 2269-2276.
16. Bakchine S, Loft H (2007) Memantine treatment in patients with mild to moderate Alzheimer's disease: Results of a randomised, double-blind, placebo-controlled-6-month study. J Alzheimers Dis 11, 471-479.
17. Rodda J, Morgan S, Walker Z (2009) Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 21, 813-824.
18. Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M (2013) A meta-analysis of the efficacy of donepezil, rivastig-mine, galantamine, and memantine in relation to severity of Alzheimer's disease. J Alzheimers Dis 35, 349-361.
19. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Ben-tham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366, 893-903.
20. Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, Covinsky KE (2002) Patient and caregiver characteristics and nursing home placement in patients with dementia.JAMA 287, 2090-2097.
21. Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, Ballard C, Boustani M, Katona C, Livingston G (2012) Efficacy of memantine for agitation in Alzheimer's dementia: A randomised double-blind placebo controlled trial. PLoS One 7, e35185.
22. Campbell N, Ayub A, Boustani MA, Fox C, Farlow M, Maid-ment I, Howard R (2008) Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: A meta-analysis. Clin Interv Aging 3, 719-728.
23. Cummings JL, Mackell J, Kaufer D (2008) Behavioral effects of current Alzheimer's disease treatments: A descriptive review. Alzeimers Dement 4, 49-60.
24. Lockhart IA, Orme ME, Mitchell SA (2011) The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: Systematic review and meta-analysis. Dement Geriatr Cogn Disord Extra 1, 212-227.